Form 8-K - Current report:
SEC Accession No. 0001682852-23-000002
Filing Date
2023-01-03
Accepted
2023-01-03 07:05:38
Documents
17
Period of Report
2023-01-03
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K mrna-20230103.htm   iXBRL 8-K 37611
2 EX-99.1 exhibit991-01032023lettert.htm EX-99.1 41344
6 image_01a.jpg GRAPHIC 236726
7 image_0a.jpg GRAPHIC 29394
8 image_1.jpg GRAPHIC 398434
9 imagea.jpg GRAPHIC 2451
  Complete submission text file 0001682852-23-000002.txt   1146863

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT mrna-20230103.xsd EX-101.SCH 1905
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT mrna-20230103_lab.xml EX-101.LAB 23832
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT mrna-20230103_pre.xml EX-101.PRE 12510
11 EXTRACTED XBRL INSTANCE DOCUMENT mrna-20230103_htm.xml XML 11354
Mailing Address 200 TECHNOLOGY SQUARE CAMBRIDGE MA 02139
Business Address 200 TECHNOLOGY SQUARE CAMBRIDGE MA 02139 6177146500
Moderna, Inc. (Filer) CIK: 0001682852 (see all company filings)

EIN.: 813467528 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38753 | Film No.: 23500179
SIC: 2836 Biological Products, (No Diagnostic Substances)